{
    "organizations": [],
    "uuid": "4183597f28d209cc9d2b4cd4c7660ef95e947d31",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novo-nordisk-to-initiate-cardiovas/brief-novo-nordisk-to-initiate-cardiovascular-outcomes-study-with-diabetes-drug-ozempic-in-2018-idUSC7N1JW01H",
    "ord_in_thread": 0,
    "title": "BRIEF-Novo Nordisk To Initiate Cardiovascular Outcomes Study With Diabetes Drug Ozempic in 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - NOVO NORDISK‘S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN SAYS:\n* LARGE CV OUTCOMES STUDY TO BE INITIATED MID-2018 WITH DIABETES DRUG OZEMPIC; RESULTS DUE AROUND 2023\n* THE STUDY WILL INCLUDE 13,000 PATIENTS FURTHER COMPANY COVERAGE: (Reporting by Jacob Grønholt-Pedersen)\n ",
    "published": "2018-02-01T18:32:00.000+02:00",
    "crawled": "2018-02-02T13:16:17.084+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "novo",
        "nordisk",
        "chief",
        "scientific",
        "officer",
        "mads",
        "krogsgaard",
        "thomsen",
        "say",
        "large",
        "cv",
        "outcome",
        "study",
        "initiated",
        "diabetes",
        "drug",
        "ozempic",
        "result",
        "due",
        "around",
        "study",
        "include",
        "patient",
        "company",
        "coverage",
        "reporting",
        "jacob"
    ]
}